Cancer biologics Global Market Report 2025

Description

Cancer biologics encompass substances derived from living organisms or their byproducts, utilized in the prevention, detection, or treatment of cancer and related disorders. These agents include immunoglobulins, interleukins, and vaccines among others. Biological therapy, a cancer treatment method, harnesses the body's immune system to combat cancer cells effectively.

The primary categories of cancer biologics consist of monoclonal antibodies, vaccines, cell and gene therapy, and other specialized therapies. Monoclonal antibodies, developed through cloning a single white blood cell, originate from a singular parent cell and have widespread application in various cancer types such as non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancer, and more. These biologics are distributed through diverse channels including hospitals, clinics, and other healthcare facilities to aid in cancer treatment and care.

The cancer biologics market research report is one of a series of new reports from The Business Research Company that provides cancer biologics market statistics, including cancer biologics industry global market size, regional shares, competitors with a cancer biologics market share, detailed cancer biologics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biologics industry. This cancer biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer biologics market size has grown rapidly in recent years. It will grow from $106.2 billion in 2024 to $117.03 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to the rising incidence of cancer, increasing awareness of cancer biologics, improved efficacy and safety of cancer biologics, approval of new cancer biologics, and growing acceptance of combination therapy.

The cancer biologics market size is expected to see strong growth in the next few years. It will grow to $168.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to expanding indications, combination therapies, real-world evidence, gene and cell therapies. Major trends in the forecast period include advances in biotechnology, personalized cancer biologics, biobetters, biosimilars, patient support services, and companion diagnostics.

The increasing prevalence of chronic diseases is a significant factor propelling the growth of the cancer biologics market. Chronic disorders are long-lasting diseases that negatively impact the health of individuals, and cancer is among the most prevalent chronic diseases. Common types of cancer include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, in February 2024, reports from the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, indicated that an increasing number of Americans are managing multiple chronic conditions, with 42% facing two or more, and 12% dealing with five or more. As a result, the growing prevalence of chronic diseases is expected to significantly contribute to the growth of the cancer biologics market in the coming years.

The upsurge in investments directed towards cancer research is predicted to act as a catalyst in driving the expansion of the cancer biologics market. Investments in cancer research denote financial backing channeled towards scientific endeavors aimed at comprehensively understanding, preventing, diagnosing, and treating cancer. Heightened funding in this domain empowers pharmaceutical and biotechnology entities to delve into pioneering discoveries, rigorous testing, and development of novel cancer biologics, including drug target identification and potential candidate synthesis. For instance, in March 2022, the Australian-based government agency, the Department of Health and Aged Care, allocated $893.5 million to bolster cancer services and outcomes. Part of this investment, around $329.4 million, supports the introduction of new cancer medications like Trodelvy, Lynparza, and Mylotarg, designed for various cancer types, benefiting a substantial number of patients annually. Consequently, increased investment in cancer research is expected to propel the growth of the cancer biologics market moving forward.

Entities within the cancer biologics market are actively engaged in developing predictive biomarkers, aiding physicians in treatment decisions by leveraging physiological indicators for performance prediction. Predictive biomarkers meticulously examine tumor growth in patients by scrutinizing major causative factors, given the distinct etiology of cancer among individuals. These biomarkers serve not only in early cancer detection but also in determining the most cost-effective treatment approaches, especially concerning biologics rooted in gene therapy.

Major players in the cancer biologics market are intensively focused on crafting cancer biosimilars, exemplified by ONTRUZAN, to secure a competitive edge. ONTRUZAN, a biosimilar drug, is specifically formulated to address various cancer forms, encompassing breast and gastric cancer treatments. In November 2022, Organon, a Canada-based women's health firm, launched ONTRUZAN, a Herceptin biosimilar, broadening the therapeutic options for Canadian adults confronting early breast cancer (EBC), metastatic breast cancer (MBC), and metastatic gastric cancer (MGC). This strategic inclusion of biosimilars into breast and gastric cancer treatments aims to expand access to cost-effective medications, thereby fostering avenues for continual reinvestment in healthcare system innovations.

In November 2022, Biocon Biologics Ltd., an esteemed biopharmaceutical company based in India, successfully acquired the global biosimilars business situated in North America from Viatris Inc., a prominent global pharmaceutical and healthcare corporation. The specific financial details of the transaction remain undisclosed. This strategic acquisition represents Biocon's strategic move to strengthen its position within the global biosimilars market, enabling the company to provide comprehensive end-to-end solutions to a wide spectrum of patients and customers worldwide. Viatris Inc., recognized as a US-based global pharmaceutical and healthcare corporation, has specialized expertise in cancer biologics, and this acquisition is expected to augment Biocon's capabilities and further its reach in the biosimilars domain, reinforcing its commitment to advancing healthcare solutions across the globe.

Major companies operating in the cancer biologics market include AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

North America was the largest region in the cancer biologics market in 2024. The Middle East is expected to be the fastest growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The cancer biologics market consists of sales of cancer vaccines, cytokine therapy, and angiogenesis inhibitors. Values in this market are factory gate values which are the values of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Monoclonal Antibodies; Vaccines; Cell And Gene Therapy; Other Types
2) By Application: Non-small Cell Lung Cancer; Prostate Cancer; Breast Cancer; Acute Myeloid Leukemia; Lymphoma; Multiple Myeloma; Ovarian Cancer; Colorectal Cancer; Gastric Cancers; Other Applications
3) By Distribution Channel: Hospitals; Clinics; Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies; Conjugated Monoclonal Antibodies; Bispecific Monoclonal Antibodies
2) By Vaccines: Therapeutic Cancer Vaccines; Preventive Cancer Vaccines
3) By Cell And Gene Therapy: CAR T-Cell Therapy; Tumor-Infiltrating Lymphocytes (TIL) Therapy; Oncolytic Virus Therapy
4) By Other Types: Cytokines; Growth Factors; Fusion Proteins
Companies Mentioned: AbbVie Inc.; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Eli Lilly and Company; AmgenInc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r32892

1. Executive Summary

2. Cancer biologics Market Characteristics

3. Cancer biologics Market Trends And Strategies

4. Cancer biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cancer biologics Growth Analysis And Strategic Analysis Framework

5.1. Global Cancer biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cancer biologics Market Growth Rate Analysis
5.4. Global Cancer biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cancer biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cancer biologics Total Addressable Market (TAM)

6. Cancer biologics Market Segmentation

6.1. Global Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Vaccines
Cell And Gene Therapy
Other Types
6.2. Global Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-small Cell Lung Cancer
Prostate Cancer
Breast Cancer
Acute Myeloid Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Colorectal Cancer
Gastric Cancers
Other Applications
6.3. Global Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other Distribution Channels
6.4. Global Cancer biologics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Naked Monoclonal Antibodies
Conjugated Monoclonal Antibodies
Bispecific Monoclonal Antibodies
6.5. Global Cancer biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutic Cancer Vaccines
Preventive Cancer Vaccines
6.6. Global Cancer biologics Market, Sub-Segmentation Of Cell And Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
CAR T-Cell Therapy
Tumor-Infiltrating Lymphocytes (TIL) Therapy
Oncolytic Virus Therapy
6.7. Global Cancer biologics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cytokines
Growth Factors
Fusion Proteins

7. Cancer biologics Market Regional And Country Analysis

7.1. Global Cancer biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cancer biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer biologics Market

8.1. Asia-Pacific Cancer biologics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer biologics Market

9.1. China Cancer biologics Market Overview
9.2. China Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer biologics Market

10.1. India Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer biologics Market

11.1. Japan Cancer biologics Market Overview
11.2. Japan Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer biologics Market

12.1. Australia Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer biologics Market

13.1. Indonesia Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer biologics Market

14.1. South Korea Cancer biologics Market Overview
14.2. South Korea Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer biologics Market

15.1. Western Europe Cancer biologics Market Overview
15.2. Western Europe Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer biologics Market

16.1. UK Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer biologics Market

17.1. Germany Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer biologics Market

18.1. France Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer biologics Market

19.1. Italy Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer biologics Market

20.1. Spain Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer biologics Market

21.1. Eastern Europe Cancer biologics Market Overview
21.2. Eastern Europe Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer biologics Market

22.1. Russia Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer biologics Market

23.1. North America Cancer biologics Market Overview
23.2. North America Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer biologics Market

24.1. USA Cancer biologics Market Overview
24.2. USA Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer biologics Market

25.1. Canada Cancer biologics Market Overview
25.2. Canada Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer biologics Market

26.1. South America Cancer biologics Market Overview
26.2. South America Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer biologics Market

27.1. Brazil Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer biologics Market

28.1. Middle East Cancer biologics Market Overview
28.2. Middle East Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer biologics Market

29.1. Africa Cancer biologics Market Overview
29.2. Africa Cancer biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Cancer biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Cancer biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer biologics Market Competitive Landscape And Company Profiles

30.1. Cancer biologics Market Competitive Landscape
30.2. Cancer biologics Market Company Profiles
- 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cancer biologics Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company
31.2. Johnson & Johnson
31.3. Merck & Co. Inc.
31.4. Novartis AG
31.5. Pfizer Inc.
31.6. Celgene Corporation
31.7. Serum Institute of India Pvt. Ltd.
31.8. Daiichi Sankyo Company Ltd.
31.9. Seagen Inc.
31.10. Takeda Pharmaceutical Company Limited
31.11. Biogen Inc.
31.12. Vertex Pharmaceuticals Incorporated
31.13. Incyte Corporation
31.14. Karyopharm Therapeutics Inc.
31.15. Kyowa Kirin Co. Ltd.

32. Global Cancer biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer biologics Market

34. Recent Developments In The Cancer biologics Market

35. Cancer biologics Market High Potential Countries, Segments and Strategies

35.1 Cancer biologics Market In 2029 - Countries Offering Most New Opportunities
35.2 Cancer biologics Market In 2029 - Segments Offering Most New Opportunities
35.3 Cancer biologics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer